The American laboratory Moderna announced this Wednesday (8) good preliminary results of the modified version of its specific vaccine against the omicron variant of the coronavirus.
A booster dose of 50 micrograms showed a “superior antibody response … against the Ômicron variant one month after inoculation, compared to the original vaccine,” Moderna said in a statement.
Named mRNA-1273.214, this new formula is a bivalent vaccine, as it works against both the original virus and the Ômicron variant.
With the dose, the antibodies against the ômicron variant multiplied by eight, according to the company. According to Moderna CEO Stéphane Bancel, the vaccine will provide “long-term protection against the variants of concern” of the coronavirus.
“We are submitting our preliminary data and analysis to regulatory agencies, with the expectation that our bivalent booster (…) will be available by the end of the summer.” [do hemisfério norte, fim do inverno no Brasil].”
Currently, all vaccines used are based on the original strain of the virus and have shown less effectiveness against the variants that have emerged in recent months.
The FDA, the US drug regulatory agency, plans to convene a committee at the end of June to assess whether the strain of the virus used to develop current vaccines “should change and, if so, which strain(s) should (m) change. be selected(s) for Fall 2022”.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
